---
title: "Shuttle Pharmaceuticals postpones special stockholder meeting to Sept. 9; proxy deadline Sept. 8"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/297820397.md"
description: "Shuttle Pharmaceuticals has postponed its special stockholder meeting from September 3 to September 9, 2026. The proxy receipt deadline is set for 11:59 p.m. ET on September 8, 2026. This delay allows additional time for proxy solicitation and shareholder consideration of amended proposals. Previously submitted valid proxies remain effective for the reconvened meeting unless revoked."
datetime: "2026-09-02T19:03:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/297820397.md)
  - [en](https://longbridge.com/en/news/297820397.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/297820397.md)
generator: "portal-rs"
---

# Shuttle Pharmaceuticals postpones special stockholder meeting to Sept. 9; proxy deadline Sept. 8

**Shuttle Pharmaceuticals postponed its special meeting to September 9, 2026 and set a proxy receipt deadline of 11:59 p.m. ET on September 8, 2026.**

**Key Highlights:**

-   Special Meeting moved from Sept. 3, 2026 at 11:00 a.m. ET to Sept. 9, 2026 at 11:00 a.m. ET to allow additional proxy solicitation.
-   Votes must be received by 11:59 p.m. ET on Sept. 8, 2026 to be counted for the reconvened meeting.
-   Postponement gives stockholders more time to consider proposals, including amended Milestone Events disclosed in the Sept. 1, 2026 Form 8-K.
-   Previously submitted valid proxies remain valid for the reconvened meeting unless properly changed or revoked before voting.

Original SEC Filing: Shuttle Pharmaceuticals Holdings, Inc. \[ SHPH \] - 8-K - Sep. 02, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [SHPH.US](https://longbridge.com/en/quote/SHPH.US.md)

## Related News & Research

- [Shuttle Pharmaceuticals corrects pre-funded warrants issued to 9,741,751 shares as of Sept. 9](https://longbridge.com/en/news/300055467.md)
- [Shuttle Pharmaceuticals Restructures Capital Through New Securities](https://longbridge.com/en/news/299177514.md)
- [Okta CEO Todd McKinnon disposes of USD 7.83 million in common shares](https://longbridge.com/en/news/300076807.md)
- [Everpure Chief Visionary Officer John Colgrove disposes of $15.29 million in common shares](https://longbridge.com/en/news/300073078.md)
- [‘Far From Done,’ Says Top Investor About Sandisk Stock](https://longbridge.com/en/news/300141435.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**